Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM) will have its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., participate in a fireside chat at the Barclays 2022 Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) will have its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., participate in a fireside chat at the Barclays 2022 Global Healthcare Conference. The event is scheduled for March 15, 2022, at 8:30 a.m. ET, in Miami, FL. A live webcast of the discussion will be available on the company’s investor website and will be archived for 60 days. Beam is focused on precision genetic medicines using its unique base editing technology to develop innovative therapies for serious diseases.
Details
News Market Reaction – BEAM
The recorded move for BEAM in the trading session of this news was -0.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president and chief scientific officer, will participate in a fireside chat during the Barclays 2022 Global Healthcare Conference on Tuesday, March 15, 2022 at 8:30 a.m. ET. The conference will be held in Miami, FL from March 15-17, 2022.
A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.